Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


June 02, 2015 7:59 PM ET

Biotechnology

Company Overview of Therapix Biosciences Ltd.

Company Overview

Therapix Biosciences Ltd., a biopharmaceutical company, identifies and develops immunotherapy products. It offers oral antibody Anti-CD3 to treat inflammatory and autoimmune illnesses, as well as other diseases related to autoimmune disorders. The company is also involved in developing antibodies to treat Alzheimer's disease. In addition, it provides LP-306, a novel pharmaceutical product based on cannabinoids for pain management; and TRX-318, an oral monoclonal antibody for auto-immune and inflammatory diseases. The company sells its products to pharmaceutical and biotechnology companies that treat metabolic disorders and liver diseases in Israel, the United States, Europe, and Australia. I...

18 Einstein Street

Science Park

Kiryat Weizmann

Ness Ziona,  

Israel

Founded in 2004

Phone:

972 8 939 6577

Fax:

972 8 939 6574

Key Executives for Therapix Biosciences Ltd.

Therapix Biosciences Ltd. does not have any Key Executives recorded.

Therapix Biosciences Ltd. Key Developments

Therapix Biosciences Ltd. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 11:30 AM

Therapix Biosciences Ltd. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 11:30 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Therapix Bio Names Jan Turek as Chief Executive Officer

Therapix Bio announced that Jan Turek has been named Chief Executive Officer, effective as of September 22, 2014. As CEO, he will lead the company's strategic growth initiatives, including the acquisition of and investment in cannabinoid-focused companies and technologies, and the development of these assets. Turek joins Therapix with over 30 years' experience in biotech and pharmaceutical executive leadership, product development, marketing and business development. As a Partner at TCG, LLC, he has been a senior strategy and transaction advisor to a number of large and small biopharmaceutical companies.

Therapix Biosciences Ltd., Special/Extraordinary Shareholders Meeting, Aug 21, 2014

Therapix Biosciences Ltd., Special/Extraordinary Shareholders Meeting, Aug 21, 2014., at 10:00 Israel Standard Time.

Similar Private Companies By Industry

Company Name Region
JPMed Ltd. Middle East/Africa
Pro-IV Medical Ltd. Middle East/Africa
Allosterix Ltd. Middle East/Africa
Polygene Ltd. Middle East/Africa
Eloxx Pharmaceuticals, Ltd. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
October 1, 2014
Dekel Pharmaceuticals Ltd.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Therapix Biosciences Ltd., please visit www.therapixbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.